1   **Supplementary table 1. Patients' characteristics.**

2

	Gene expression peripheral blood B cells			Immunofluorescence labial salivary gland	
	HC (n=9)	nSS (n=17)	pSS (n=13)	nSS (n=6)	pSS (n=12)
Gender (female %)	100	100	77	100	100
Age (yr)	57±5	53±15	52±12	40±18	48±11
Anti-Ro/SSA+ (%)	NA	41	62	0	100
Anti-La/SSB+ (%)	NA	0	38	0	50
LFS (foci/4mm^2)	NA	0	1.8±1.1	0	3.7±2.5
IgG and IgM+ plasma cells in LSG biopsy (%)	NA	31±14	52±19	20±7	54±18
Serum IgG (g/L)	NA	11.2±2.9	17.1±9.3	9.7±2.6	20.1±9.1
ESR (mm/h)	NA	14±12	15±12	17±9	38±25
<u>Schirmer (mm/5min)</u>	<u>NA</u>	<u>5.9±7.2</u>	<u>5.8±9.0</u>	<u>13.8±15.9</u>	<u>5.9±6.0</u>
ESSDAI (0-123)	NA	NA	4±6	NA	NA
ESSPRI (0-10)	NA	NA	5±3	NA	NA

3

4   HC: healthy controls; nSS: non-Sjögren's sicca; pSS: primary Sjögren's syndrome; LFS:

5   lymphocytic focus score; LSG: labial salivary gland; ESR: erythrocyte sedimentation rate;

6   ESSDAI: EULAR Sjögren's syndrome disease activity index; ESSPRI: EULAR Sjögren's

1

1   syndrome patient reported index. Data represent Mean±SD unless specified differently. At

2   the time that the biopsies of the immunofluorescence cohort were taken, ESSDAI and

3   ESSPRI were not published, and therefore these are not shown.

2